Outcomes in PMBL: a retrospective analysis
Research type
Research Study
Full title
Impact of induction and subsequent chemo-radiotherapy on outcomes in primary mediastinal large B-cell lymphoma: a retrospective analysis
IRAS ID
253710
Contact name
Mark Bishton
Contact email
Sponsor organisation
R&I, Nottingham University Hospitals NHS Trust
Duration of Study in the UK
1 years, 0 months, 28 days
Research summary
Primary mediastinal large B-cell lymphoma (PMBL) is a rare type of aggressive lymphoma and usually presents in young female patients. Treatment outcomes are generally favourable, however, significant numbers of patients do not respond to treatment, or quickly relapse afterwards. These patients are thought to have a very poor prognosis despite salvage chemotherapy and stem cell transplantation.
CT-PET is used to assess response in many types of lymphoma. Post treatment assessment in PMBL using CT-PET scans is difficult as there is often residual activity in patients who later are shown to have been cured, and more information is needed to understand which patients are likely to have poor outcomes. This study will involve the collection of data regarding the diagnosis and treatment of patients with PMBL in whom a PET/CT scan has been done at diagnosis and/or after treatment.
The aims of the study are to
1. Assess impact of initial treatment on clinical outcomes.
2. Among patients with relapsed/refractory disease, describe outcomes following salvage therapy.
3. To define management patterns and clinical outcomes for patients with positive end of treatment CT-PET scans.
4. To assess impact of the findings on pre-treatment CT-PET with response to induction therapy.
Data will will be collected from NUH clinical records and will be analysed centrally in Australia. Anonymised outcome data will be sent to Australia, in addition to anonymised CT-PET images for review.REC name
East Midlands - Nottingham 2 Research Ethics Committee
REC reference
19/EM/0256
Date of REC Opinion
7 Aug 2019
REC opinion
Favourable Opinion